2. Signaling Pathways
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CCR
  5. CCR6 Isoform

CCR6

CCR6 (C-C chemokine receptor 6) is a class A G protein-coupled chemokine receptor that regulates leukocyte trafficking, immune homeostasis, and inflammatory cell recruitment through its highly selective interaction with CCL20.[1][2] CCR6 is expressed on immature dendritic cells, memory T cells, B cells, Th17 cells, and regulatory T cells, positioning the receptor at the interface between adaptive immunity and tissue-specific inflammatory responses.[1][3][4] Mechanistically, the CCR6-CCL20 axis directs chemotaxis and cellular localization within mucosal and epithelial tissues, where it contributes to immune surveillance and maintenance of barrier function.[2][5] In inflammatory disease models, CCR6 signaling promotes recruitment of Th17 cells and regulates the Th17/Treg balance, a process implicated in chronic intestinal inflammation, autoimmune disorders, and tissue injury.[1][2] Experimental studies in inflammatory bowel disease have demonstrated that disruption of CCR6-dependent signaling can reduce colonic inflammation and alter mucosal immune responses.[1][2] Compared with many chemokine receptors that interact with multiple ligands, CCR6 is distinguished by its largely exclusive, high-affinity interaction with CCL20, providing a comparatively specific model for studying chemokine-directed immune regulation.[1][4] Structural analyses further show that CCR6 functions as a seven-transmembrane receptor coupled primarily to Gi/o proteins, supporting mechanistic investigations of receptor activation and downstream signaling.[6] For experimental applications, the CCR6/CCL20 pathway is widely used to investigate immune-cell migration, inflammatory disease mechanisms, and the therapeutic potential of receptor-targeted antibodies designed to modulate pathological leukocyte recruitment.[1]

Cat. No. Product Name Effect Purity
  • HY-151435
    CCR6 antagonist 1
    		Antagonist 99.30%
    CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).
  • HY-112701
    CCR6 inhibitor 1
    		Inhibitor 99.60%
    CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC50s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC50, > 30000 nM), and CCR7 (IC50, 9400 nM). CCR6 inhibitor 1 markedly blocks ERK phosphorylation. CCR6 inhibitor 1 is used in the research of autoimmune diseases and cancer.
  • HY-148531
    PF-07054894
    		Inhibitor 99.15%
    PF-07054894 is an orally active and potent C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) antagonist that blocks CCR6-mediated chemotaxis with an IC50 value of 5.7 nM in vitro. PF-07054894 targets G protein-coupled receptor (GPCR). PF-07054894 can be used in research of inflammatory bowel disease.
  • HY-162495
    IDOR-1117-2520
    		Antagonist 99.94%
    IDOR-1117-2520 is an orally active, potent, selective and reversible CCR6 antagonist. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC50 = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC50 = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 is found to be a substrate of P-gp/MDR1. IDOR-1117-2520 can be used in the research of autoimmune diseases and skin inflammation.
  • HY-162495A
    (S)-IDOR-1117-2520
    		Antagonist 99.47%
    (S)-IDOR-1117-2520 is the S-isomer of IDOR-1117-2520 (HY-162495). IDOR-1117-2520 is an orally active, potent, selective and reversible CCR6 antagonist. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC50 = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC50 = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 is found to be a substrate of P-gp/MDR1. IDOR-1117-2520 can be used in the research of autoimmune diseases and skin inflammation.
  • HY-176980
    CCR6 antagonist 4
    		Antagonist
    CCR6 antagonist 4 (compound OXM1) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 158 nM). CCR6 antagonist 4 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 4 can be used for chronic inflammatory diseases research.
  • HY-176979
    CCR6 antagonist 3
    		Antagonist
    CCR6 antagonist 3 (compound OXM2) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 166 nM). CCR6 antagonist 3 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 3 can be used for chronic inflammatory diseases research.
Cat. No. Product Name / Synonyms Species Source